The patterns of relapse in osteosarcoma: The Memorial Sloan-Kettering experience Journal Article
| Authors: | Chi, S. N.; Conklin, L. S.; Qin, J.; Meyers, P. A.; Huvos, A. G.; Healey, J. H.; Gorlick, R. |
| Article Title: | The patterns of relapse in osteosarcoma: The Memorial Sloan-Kettering experience |
| Abstract: | Background. With the introduction of intensive high-dose chemotherapy for the treatment of osteosarcoma, changes in the pattern of metastases observed at relapse have been reported. To further investigate this hypothesis, the relapse patterns among groups receiving chemotherapy regimens of variable intensity at Memorial Sloan-Kettering Cancer Center were analyzed. Procedure. All patients treated with the protocols T4, T5, T7, T10, and T12 were included. Patients were divided into two groups, one including those patients treated with less intense therapy (T4, T5, and T7) and the other, those treated with current regimens (T10 and T12). Results. Of the 25 patients who relapsed on the earlier protocols, 76% relapsed to the lungs, 8% had local recurrences, and 16% distant metastases to the bone. The median time to first relapse was 12 months. Of the 69 patients who relapsed on the T10 and T12 protocols, 75% relapsed in the lungs, 9% had local recurrences, and 16% distant bone metastases. The median time to first relapse was 17 months. There was no statistically significant difference in the timing of relapse between the two groups studied, although a longer median time to relapse was observed for patients treated on the later protocols. The range of time to relapse was also wider in the later protocols. Conclusions. These data do not support the hypothesis that patterns of relapse are changing with alterations in osteosarcoma treatment. This limited single institutional experience can be explored further in the context of a multi-institutional effort. © 2003 Wiley-Liss, Inc. |
| Keywords: | osteosarcoma; clinical article; controlled study; treatment outcome; bone neoplasms; disease-free survival; survival rate; disease course; cancer recurrence; cisplatin; doxorubicin; united states; bone metastasis; cancer adjuvant therapy; chemotherapy, adjuvant; neoadjuvant therapy; methotrexate; drug megadose; follow up; antineoplastic agent; cancer grading; low drug dose; computer assisted tomography; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; lung neoplasms; cyclophosphamide; vincristine; clinical protocol; childhood cancer; lung metastasis; symptom; cancer regression; folinic acid; adjuvant chemotherapy; dactinomycin; remission induction; bleomycin; outcomes research; thorax radiography; drug dose regimen; bone scintiscanning; humans; human; priority journal; article; relapse patterns |
| Journal Title: | Pediatric Blood and Cancer |
| Volume: | 42 |
| Issue: | 1 |
| ISSN: | 1545-5009 |
| Publisher: | Wiley Periodicals, Inc |
| Date Published: | 2004-01-01 |
| Start Page: | 46 |
| End Page: | 51 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 14752794 |
| DOI: | 10.1002/pbc.10420 |
| DOI/URL: | |
| Notes: | Pediatr. Blood Cancer -- Cited By (since 1996):31 -- Export Date: 16 June 2014 -- CODEN: PBCEA C2 - 14752794 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work